Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics
CORT Price/Volume Stats
Current price | $22.49 | 52-week high | $34.28 |
Prev. close | $22.26 | 52-week low | $17.86 |
Day low | $22.13 | Volume | 1,023,400 |
Day high | $22.62 | Avg. volume | 2,276,437 |
50-day MA | $26.01 | Dividend yield | N/A |
200-day MA | $26.40 | Market Cap | 2.32B |
CORT Stock Price Chart Interactive Chart >
CORT POWR Grades
- Quality is the dimension where CORT ranks best; there it ranks ahead of 99.92% of US stocks.
- CORT's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- CORT ranks lowest in Momentum; there it ranks in the 18th percentile.
CORT Stock Summary
- For CORT, its debt to operating expenses ratio is greater than that reported by just 3.62% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.21 for CORCEPT THERAPEUTICS INC; that's greater than it is for only 13.68% of US stocks.
- With a year-over-year growth in debt of -86.82%, CORCEPT THERAPEUTICS INC's debt growth rate surpasses merely 1.61% of about US stocks.
- Stocks that are quantitatively similar to CORT, based on their financial statements, market capitalization, and price volatility, are ACMR, ALRM, ALGM, WATT, and LGVN.
- Visit CORT's SEC page to see the company's official filings. To visit the company's web site, go to www.corcept.com.
CORT Valuation Summary
- In comparison to the median Healthcare stock, CORT's price/sales ratio is 236.36% higher, now standing at 7.4.
- CORT's price/sales ratio has moved NA NA over the prior 240 months.
Below are key valuation metrics over time for CORT.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CORT | 2023-12-29 | 7.4 | 7.3 | 36.8 | 33.2 |
CORT | 2023-12-28 | 7.5 | 7.3 | 37.3 | 33.6 |
CORT | 2023-12-27 | 7.5 | 7.3 | 37.2 | 33.5 |
CORT | 2023-12-26 | 7.4 | 7.2 | 36.8 | 33.1 |
CORT | 2023-12-22 | 7.5 | 7.3 | 37.2 | 33.5 |
CORT | 2023-12-21 | 7.3 | 7.1 | 35.9 | 32.3 |
CORT Growth Metrics
- The 5 year cash and equivalents growth rate now stands at 122.45%.
- Its year over year net cashflow from operations growth rate is now at 23.31%.
- Its 4 year net cashflow from operations growth rate is now at 490.98%.
The table below shows CORT's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 401.858 | 120.323 | 101.288 |
2022-09-30 | 397.624 | 136.362 | 116.798 |
2022-06-30 | 392.027 | 151.418 | 112.719 |
2022-03-31 | 380.229 | 177.717 | 111.844 |
2021-12-31 | 365.978 | 167.892 | 112.512 |
2021-09-30 | 352.891 | 153.536 | 106.453 |
CORT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CORT has a Quality Grade of A, ranking ahead of 98.86% of graded US stocks.
- CORT's asset turnover comes in at 0.616 -- ranking 52nd of 681 Pharmaceutical Products stocks.
- OTIC, ABT, and AVDL are the stocks whose asset turnover ratios are most correlated with CORT.
The table below shows CORT's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.616 | 0.985 | 0.237 |
2021-03-31 | 0.631 | 0.985 | 0.248 |
2020-12-31 | 0.691 | 0.984 | 0.312 |
2020-09-30 | 0.754 | 0.984 | 0.345 |
2020-06-30 | 0.816 | 0.983 | 0.413 |
2020-03-31 | 0.862 | 0.982 | 0.432 |
CORT Price Target
For more insight on analysts targets of CORT, see our CORT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $25.25 | Average Broker Recommendation | 1.75 (Moderate Buy) |
Corcept Therapeutics Incorporated (CORT) Company Bio
Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.
Latest CORT News From Around the Web
Below are the latest news stories about CORCEPT THERAPEUTICS INC that investors may wish to consider to help them evaluate CORT as an investment opportunity.
Corcept Therapeutics Inc's Chief Development Officer Sells SharesOn December 22, 2023, Chief Development Officer William Guyer sold 10,000 shares of Corcept Therapeutics Inc (NASDAQ:CORT), as reported in a recent SEC Filing. |
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Could Be 36% Below Their Intrinsic Value EstimateKey Insights Corcept Therapeutics' estimated fair value is US$41.23 based on 2 Stage Free Cash Flow to Equity Corcept... |
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Insider Sell: Joseph Lyon of Corcept Therapeutics Inc (CORT) Sells 5,000 SharesJoseph Lyon, the Chief Accounting Officer of Corcept Therapeutics Inc, has recently made a significant stock transaction, selling 5,000 shares of the company on December 4, 2023. |
CORT Price Returns
1-mo | -10.40% |
3-mo | -10.15% |
6-mo | -27.15% |
1-year | -4.09% |
3-year | -26.41% |
5-year | 98.15% |
YTD | -30.76% |
2023 | 59.92% |
2022 | 2.58% |
2021 | -24.31% |
2020 | 116.20% |
2019 | -9.43% |
Continue Researching CORT
Here are a few links from around the web to help you further your research on Corcept Therapeutics Inc's stock as an investment opportunity:Corcept Therapeutics Inc (CORT) Stock Price | Nasdaq
Corcept Therapeutics Inc (CORT) Stock Quote, History and News - Yahoo Finance
Corcept Therapeutics Inc (CORT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...